|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:affiliatedWith
|
gptkb:benzodiazepines
|
|
gptkbp:approvedBy
|
1963
|
|
gptkbp:ATCCode
|
N05BA01
|
|
gptkbp:availableOn
|
gptkb:tablet
oral solution
injectable solution
rectal gel
|
|
gptkbp:cause
|
addiction
tolerance
withdrawal syndrome
|
|
gptkbp:chemicalFormula
|
C16H13ClN2O
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
severe respiratory insufficiency
sleep apnea syndrome
hypersensitivity to benzodiazepines
severe hepatic insufficiency
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:developedBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:discoveredBy
|
gptkb:Leo_Sternbach
|
|
gptkbp:effect
|
benzodiazepine
sedative
anticonvulsant
muscle relaxant
|
|
gptkbp:eliminationHalfLife
|
20-70 hours
|
|
gptkbp:excretion
|
kidneys
|
|
gptkbp:genericName
|
gptkb:diazepam
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Valium
|
|
gptkbp:interactsWith
|
gptkb:beer
opioids
other CNS depressants
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
284.7 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
rectal
|
|
gptkbp:sideEffect
|
confusion
fatigue
muscle weakness
drowsiness
impaired coordination
dependence
withdrawal symptoms
|
|
gptkbp:usedFor
|
seizures
anxiety disorders
muscle spasms
alcohol withdrawal symptoms
sedation before medical procedures
|
|
gptkbp:bfsParent
|
gptkb:Roche
gptkb:diazepam
|
|
gptkbp:bfsLayer
|
6
|